https://retacompare.com/news/concerns-about-glp-1s-for-weight-loss-highlighted-in-recent-report 2026-10-27T13:00:14.000Z RetatrutideCompare en 2026-10-27T13:00:14.000Z Concerns About GLP-1s for Weight Loss Highlighted in Recent Report Weight Loss, Retatrutide https://retacompare.com/news/patient-satisfaction-with-glp-1-weight-loss-drugs-explored 2026-10-27T08:50:32.000Z RetatrutideCompare en 2026-10-27T08:50:32.000Z Patient Satisfaction with GLP-1 Weight Loss Drugs Explored Patient Experiences, Retatrutide https://retacompare.com/news/glp-1-agonist-misinformation-challenges-primary-care-providers 2026-10-27T08:34:49.000Z RetatrutideCompare en 2026-10-27T08:34:49.000Z GLP-1 Agonist Misinformation Challenges Primary Care Providers Patient Experiences, Retatrutide https://retacompare.com/news/glp-1-drugs-examining-benefits-and-risks-in-eating-disorders 2026-10-27T03:28:25.000Z RetatrutideCompare en 2026-10-27T03:28:25.000Z GLP-1 Drugs: Examining Benefits and Risks in Eating Disorders Weight Loss, Retatrutide https://retacompare.com/news/corxel-plans-public-debut-via-spac-to-boost-obesity-drug-development 2026-10-26T20:23:56.000Z RetatrutideCompare en 2026-10-26T20:23:56.000Z Corxel Plans Public Debut via SPAC to Boost Obesity Drug Development Market News, Retatrutide https://retacompare.com/news/corxel-to-go-public-amid-advancements-in-oral-glp-1-agonists 2026-10-26T20:06:24.000Z RetatrutideCompare en 2026-10-26T20:06:24.000Z Corxel to Go Public Amid Advancements in Oral GLP-1 Agonists Market News, Retatrutide https://retacompare.com/news/corxel-plans-public-listing-with-focus-on-glp-1-and-amylin-obesity-drugs 2026-10-26T19:17:00.000Z RetatrutideCompare en 2026-10-26T19:17:00.000Z Corxel Plans Public Listing with Focus on GLP-1 and Amylin Obesity Drugs Market News, Retatrutide https://retacompare.com/news/amgen-s-glp-1-obesity-drug-development-progress-discussed 2026-10-26T19:15:01.000Z RetatrutideCompare en 2026-10-26T19:15:01.000Z Amgen's GLP-1 Obesity Drug Development Progress Discussed Market News, Retatrutide https://retacompare.com/news/unexpected-advantages-of-glp-1-agonists-beyond-glycemic-control 2026-10-26T16:40:00.000Z RetatrutideCompare en 2026-10-26T16:40:00.000Z Unexpected Advantages of GLP-1 Agonists Beyond Glycemic Control Patient Experiences, Retatrutide https://retacompare.com/news/medicare-glp-1-program-requires-new-pharmacy-workflow 2026-10-26T16:32:47.000Z RetatrutideCompare en 2026-10-26T16:32:47.000Z Medicare GLP-1 Program Requires New Pharmacy Workflow Market News, Retatrutide https://retacompare.com/news/retatrutide-shows-potential-sleep-benefits-in-obesity-treatment 2026-10-26T16:30:52.000Z RetatrutideCompare en 2026-10-26T16:30:52.000Z Retatrutide Shows Potential Sleep Benefits in Obesity Treatment Weight Loss, Retatrutide https://retacompare.com/news/novo-s-glp-1-drug-shows-promise-in-phase-ii-for-type-2-diabetes 2026-10-26T15:00:37.000Z RetatrutideCompare en 2026-10-26T15:00:37.000Z Novo's GLP-1 Drug Shows Promise in Phase II for Type 2 Diabetes Clinical Trials, Retatrutide https://retacompare.com/news/novo-s-new-drug-shows-promise-in-phase-ii-diabetes-trials 2026-10-26T15:00:37.000Z RetatrutideCompare en 2026-10-26T15:00:37.000Z Novo's New Drug Shows Promise in Phase II Diabetes Trials Clinical Trials, Retatrutide https://retacompare.com/news/examining-the-safety-of-glp-1-agonists-for-obese-adolescents 2026-10-26T13:57:41.000Z RetatrutideCompare en 2026-10-26T13:57:41.000Z Examining the Safety of GLP-1 Agonists for Obese Adolescents Clinical Trials, Retatrutide https://retacompare.com/news/latest-developments-in-glp-1-agonists-and-retatrutide-research 2026-10-26T09:10:15.000Z RetatrutideCompare en 2026-10-26T09:10:15.000Z Latest Developments in GLP-1 Agonists and Retatrutide Research Market News, Retatrutide https://retacompare.com/news/retatrutide-trial-shows-promising-weight-loss-results-by-eli-lilly 2026-10-26T06:28:20.000Z RetatrutideCompare en 2026-10-26T06:28:20.000Z Retatrutide Trial Shows Promising Weight Loss Results by Eli Lilly Clinical Trials, Retatrutide https://retacompare.com/news/latest-developments-in-glp-1-agonists-for-obesity-treatment 2026-10-26T03:11:12.000Z RetatrutideCompare en 2026-10-26T03:11:12.000Z Latest Developments in GLP-1 Agonists for Obesity Treatment Market News, Retatrutide https://retacompare.com/news/potential-impact-of-glp-1-drugs-on-crohn-s-and-ulcerative-colitis-explored 2026-10-26T03:00:48.000Z RetatrutideCompare en 2026-10-26T03:00:48.000Z Potential Impact of GLP-1 Drugs on Crohn's and Ulcerative Colitis Explored Clinical Trials, Retatrutide https://retacompare.com/news/exploring-adult-weight-loss-drugs-for-pediatric-obesity-treatment 2026-10-26T02:49:41.368Z RetatrutideCompare en 2026-10-26T02:49:41.368Z Exploring Adult Weight-Loss Drugs for Pediatric Obesity Treatment Weight Loss, Retatrutide https://retacompare.com/news/impact-of-cardiorenal-metabolic-therapies-on-skeletal-muscle-explored 2026-10-26T00:00:00.000Z RetatrutideCompare en 2026-10-26T00:00:00.000Z Impact of Cardiorenal-Metabolic Therapies on Skeletal Muscle Explored Clinical Trials, Retatrutide https://retacompare.com/news/glp-1-agonists-show-weight-loss-in-breast-cancer-patients-on-endocrine-therapy 2026-10-26T00:00:00.000Z RetatrutideCompare en 2026-10-26T00:00:00.000Z GLP-1 Agonists Show Weight Loss in Breast Cancer Patients on Endocrine Therapy Weight Loss, Retatrutide https://retacompare.com/news/approaches-to-pediatric-obesity-and-cardiometabolic-risk-management 2026-10-26T00:00:00.000Z RetatrutideCompare en 2026-10-26T00:00:00.000Z Approaches to Pediatric Obesity and Cardiometabolic Risk Management Weight Loss, Retatrutide https://retacompare.com/news/eli-lilly-s-retatrutide-advances-in-weight-loss-drug-development-2 2026-10-25T22:36:24.000Z RetatrutideCompare en 2026-10-25T22:36:24.000Z Eli Lilly's Retatrutide Advances in Weight Loss Drug Development Weight Loss, Retatrutide https://retacompare.com/news/comparing-weight-loss-drugs-tirzepatide-semaglutide-and-retatrutide 2026-10-25T21:52:16.000Z RetatrutideCompare en 2026-10-25T21:52:16.000Z Comparing Weight Loss Drugs: Tirzepatide, Semaglutide, and Retatrutide Market News, Retatrutide https://retacompare.com/news/eli-lilly-s-retatrutide-advances-in-weight-loss-drug-development 2026-10-25T21:01:34.000Z RetatrutideCompare en 2026-10-25T21:01:34.000Z Eli Lilly's Retatrutide Advances in Weight Loss Drug Development Weight Loss, Retatrutide https://retacompare.com/news/retatrutide-new-developments-in-glp-1-agonist-obesity-treatments 2026-10-25T20:35:04.000Z RetatrutideCompare en 2026-10-25T20:35:04.000Z Retatrutide: New Developments in GLP-1 Agonist Obesity Treatments Weight Loss, Retatrutide https://retacompare.com/news/recent-developments-in-glp-1-agonists-and-retatrutide-highlighted 2026-10-25T20:03:43.000Z RetatrutideCompare en 2026-10-25T20:03:43.000Z Recent Developments in GLP-1 Agonists and Retatrutide Highlighted Market News, Retatrutide